Healthy volunteers
Conditions
Interventions
Subjects will receive two tablet of levonorgestrel tablet 0.75 mg (Postinor®) by oral route under fasting condition.,Subjects will receive one tablet of levonorgestrel tablet 1.5 mg (Test product) by
Active Comparator Drug,Active Comparator Drug
levonorgestrel tablet 1.5 mg (Postinor®1),levonorgestrel tablet 1.5 mg (Test product)
Sponsors
Pharmacy Service Center, Faculty of Pharmacy, Chiang Mai University
Pharmacy Service Center,
Faculty of Pharmacy,
Chiang Mai University
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1) Healthy male and female subjects based on medical history and physical examination, aged between 18-45 years. 2) Normal or not clinically significant abnormal of clinical laboratory results including blood urea nitrogen (BUN), serum creatinine (SCr), AST, ALT, total bilirubin, direct bilirubin, alkaline phosphatase, total protein, fasting blood glucose, complete blood count and urinalysis. 3) Clinical laboratory result of hepatitis B is negative. 4) No clinically significant findings in vital sign measurement. 5) Body Mass Index (BMI) between 18.5-25.0 kg/m2 and body weight is not less than 45 kg. 6) Nonsmoker or stop smoking for at least 6 months. 7) Females who participate in this study must: 7.1) Be nonpregnant female (negative result for pregnancy test). 7.2) Commit to use acceptable non-hormonal contraceptive method of birth control for at least 2 weeks before and during the study as judged by the clinical investigators, such as condoms, non-hormonal intrauterine device (IUD), or willing to remain abstinence (not engage in sexual intercourse) , if there is childbearing potential. 7.3) Be not currently breastfeeding. 8) Subjects are able, willing to comply with study procedures and restrictions.
Exclusion criteria
Exclusion criteria: 1) Subjects with a history of allergy to levonorgestrel or related structure of levonorgestrel or other components in the formulation 2) Subjects with currently or history of alcohol addiction or drug abuse 3) Subjects with currently or history of severe asthma, lung disease, seizures, gastrointestinal bleeding or ulcer, heart rhythm problem, hepatic, renal, endocrine, or cardiovascular diseases or any other conditions that may affect bioavailability of the medication or safety of the subjects 4) Subjects who use of any medication including vitamins, herbal products, and dietary supplement, within 14 days before and during the study 5) Subjects who are unable to refrain from consumption of orange, pamelo, grapefruit within 7 days before and during the study 6) Subjects who are unable to refrain from caffeine-containing beverages and foods such as tea, coffee, cocoa, cola, chocolate or energy drink for 3 days before and during the study 7) Subjects with positive urine drug abuse test (methamphetamine, cannabinoid and opiates) 8) Subjects with positive alcohol breath test 9) Subjects with a history of blood donation greater than 300 ml or significant blood loss within 90 days before the initiation of the study 10) Subjects who participate in other clinical trials within 90 days before the initiation of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| levonorgestrel concentration in plasma 0.0,0.5,0.75,1.0,1.25,1.5,1.75,2.0,2.5,3.0,4.0,6.0,8.0,10.0,12.0,24.0,36.0,48.0, and 72.0h Cmax, AUC(0-72h), AUC(0-inf),Area Under the Plasma Concentration Time Curve From 0-72h; AUC(0-72h) 0.0,0.5,0.75,1.0,1.25,1.5,1.75,2.0,2.5,3.0,4.0,6.0,8.0,10.0,12.0,24.0,36.0,48.0, and 72.0h LC-MS/MS,Area Under the Plasma Concentration Time Curve From 0-inf;AUC(0-inf) 0.0,0.5,0.75,1.0,1.25,1.5,1.75,2.0,2.5,3.0,4.0,6.0,8.0,10.0,12.0,24.0,36.0,48.0, and 72.0h LC-MS/MS | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Public ContactNarawadee Niamhun
Faculty of Pharmacy, Chiang Mai University
Outcome results
None listed